Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

IP3/DAG Signaling Pathway

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...

Amplifying Signals via Second Messengers

Amplifying Signals via Second Messengers

Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...

Phosphoinositides and PIPs

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A novel noncanonical Src-mammalian STE20-like kinase 1 (MST1)-Akt/glycogen synthase kinase-3β (GSK3β) pathway drives platelet activation and thrombosis.

Journal of thrombosis and haemostasis : JTH·2026

Same author

Additive effects of ceftiofur-neomycin combination against multidrug-resistant pathogenic <i>Escherichia coli</i> in a murine infection model.

Veterinarni medicina·2026

Same author

Standardization of canine platelet-rich plasma preparation and its functional characterization.

Journal of veterinary science·2026

Same author

Case Report: Dose-dependent response to oclacitinib in a dog with Sézary syndrome.

Frontiers in veterinary science·2025

Same author

Insights into <i>Campula oblonga</i> (Digenea: Brachycladiidae): Morphological, phylogenetic, and pathological studies in narrow-ridged finless porpoise (<i>Neophocaena asiaeorientalis</i>) from Korean waters.

International journal for parasitology. Parasites and wildlife·2025

Same author

The Efficacy of Intrathecal Platelet-Rich Plasma Administration in Alleviation of Chronic Neuropathic Pain in Rat Model.

Molecular neurobiology·2025

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

P2Y12 receptor in platelet activation.

Soochong Kim¹, Satya P Kunapuli

¹Department of Physiology, Temple University School of Medicine, Philadelphia, PA, USA.

|January 15, 2011

Summary

Adenosine diphosphate (ADP) is crucial for blood clotting and clot formation. Targeting the P2Y12 receptor, which ADP activates, is an effective strategy for developing antithrombotic drugs.

Area of Science:

Biochemistry
Hematology
Pharmacology

Background:

Adenosine diphosphate (ADP) is a key signaling molecule in hemostasis and thrombosis.
Platelet activation and aggregation are critical processes in thrombus formation.
The P2Y12 receptor is a primary mediator of ADP-induced platelet responses.

Purpose of the Study:

To highlight the significance of ADP in hemostasis and thrombosis.
To emphasize the central role of the P2Y12 receptor in platelet activation.
To underscore the therapeutic potential of targeting the P2Y12 receptor for antithrombotic drug development.

Main Methods:

Review of existing literature on ADP signaling in platelets.
Analysis of the P2Y12 receptor's function in thrombus formation.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Evaluation of P2Y12 receptor antagonists as antithrombotic agents.

Main Results:

ADP is essential for normal hemostatic plug formation.
P2Y12 receptor activation by ADP leads to sustained platelet aggregation.
P2Y12 receptor blockade effectively inhibits thrombus development.

Conclusions:

The P2Y12 receptor is a validated and critical target for antithrombotic therapy.
Understanding ADP-P2Y12 interactions provides a basis for novel antithrombotic drug design.
Targeting P2Y12 offers a promising approach to prevent thrombotic events.